Comparison of the sensitivity to compounds tested in this study with published spheroid models
| Cell Type | PHH | HepaRG | HepG2 | HLC | C3A | Rat Hepatocytes | |||
|---|---|---|---|---|---|---|---|---|---|
| Acute | Repeated Dose (14 Days) | Acutea,b | Repeated Dose (72 h)b | Acuteb,c,d | Repeated Dose (6 Days)c | Acuted,e | Acutef | Acuteg | |
| APAP, mM | >10 | 0.6 | 3 | ND | 24 | 9.4 | 30 | 40 | 40 |
| AFB, µM | 0.4 | 0.03 | 1.6 | ND | >200 | ND | 7 | ND | ND |
| AMD, µM | >100 | 11.9 | 178 | ND | 50–>200 | ND | 25 | 260 | ND |
| CPZ, µM | 16.6 | 4.6 | 98 | 43 | 43 | ND | ND | ND | ND |
| TRO, µM | 37.4 | 1.5 | 400 | ND | 80–150 | 100 | 50 | ND | ND |
| XIM, µM | >400 | 165 | ND | ND | ND | ND | ND | ND | ND |
AFB, aflatoxin B1; AMD, amiodarone; CPZ, chlorpromazine; HLC, Stem cell-derived hepatocyte-like cells; ND, not determined; TRO, troglitazone; XIM, ximelagatran.
↵a Gunness et al. (2013).
↵b Mueller et al. (2014).
↵c Ramaiahgari et al. (2014).
↵d Takayama et al. (2013).
↵e Tasnim et al. (2016).
↵f Fey and Wrzesinski (2012).
↵g Schutte et al. (2011).